Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Rituximab [174722-31-7]

Rituximab [174722-31-7]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-P9913-1mg

Size : 1mg

Marke : MedChemExpress

Contact local distributor :


Telefonnummer : +1 850 650 7790

Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Rituximab Chemische Struktur

Rituximab Chemische Struktur

CAS. Nr. : 174722-31-7

This product is a controlled substance and not for sale in your territory.

Based on 6 publication(s) in Google Scholar

Other Forms of Rituximab:

  • Rituximab (anti-CD20) In-stock
Beschreibung

Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Isotype

Human IgG1 kappa
Recommend Isotype Controls

Human IgG1 kappa, Isotype Control
Species

Chimeric
In Vitro

Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rituximab Related Antibodies
In Vivo

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Klinische Studie
CAS. Nr.

174722-31-7
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Rituximab]
Versand

Shipping with dry ice.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation

Purity: 99.85%

COA (291 KB)

Handling Instructions (2659 KB)
Verweise

  • [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.  [Content Brief]

    [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.  [Content Brief]

    [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.  [Content Brief]

Zellassay

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3].

MCE hat die Genauigkeit dieser Methoden nicht unabhängig bestätigt. Sie dienen nur als Referenz.
Tierverwaltung
[1]

C57BL/6 mice (8-10 wk of age) are inoculated 8×103 EL4-CD20+ cells in 200 μL of saline by tail vein injection. In parallel groups of mice, 150 g of rituximab, murine anti-CD20 IgG2a Ab 1F5, or control anti-human IL-2R Ab daclizumab in 300 μL of saline, or saline only is inoculated i.p. 24 h later[1].

MCE hat die Genauigkeit dieser Methoden nicht unabhängig bestätigt. Sie dienen nur als Referenz.
Verweise

  • [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.  [Content Brief]

    [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.  [Content Brief]

    [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.  [Content Brief]

  • [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.

    [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.

    [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Rituximab Related Classifications

  • Immunology/Inflammation
  • CD20

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rituximab174722-31-7Anti-Human CD20 type I, Chimeric AntibodyCD20Inhibitorinhibitorinhibit

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
0151K-01
Human IgG1 Kappa-UNLB
 0.5mg 
0151L-01
Human IgG1 Lambda-UNLB
 0.5mg 
A10041-50
Adriamycin [25316-40-9]
 50mg